Puma Biotechnology Past Earnings Performance
Past criteria checks 3/6
Puma Biotechnology has been growing earnings at an average annual rate of 58.9%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 3.9% per year. Puma Biotechnology's return on equity is 18%, and it has net margins of 4%.
Key information
58.9%
Earnings growth rate
59.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -3.9% |
| Return on equity | 18.0% |
| Net Margin | 4.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Revenue & Expenses Breakdown
How Puma Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 219 | 9 | 89 | 52 |
| 31 Mar 24 | 227 | 15 | 89 | 51 |
| 31 Dec 23 | 236 | 22 | 89 | 50 |
| 30 Sep 23 | 229 | 4 | 95 | 51 |
| 30 Jun 23 | 230 | -2 | 98 | 51 |
| 31 Mar 23 | 235 | 5 | 94 | 50 |
| 31 Dec 22 | 228 | 0 | 92 | 52 |
| 30 Sep 22 | 218 | 10 | 87 | 53 |
| 30 Jun 22 | 207 | -34 | 90 | 60 |
| 31 Mar 22 | 201 | -49 | 108 | 67 |
| 31 Dec 21 | 253 | -29 | 116 | 72 |
| 30 Sep 21 | 250 | -48 | 122 | 82 |
| 30 Jun 21 | 255 | -35 | 126 | 86 |
| 31 Mar 21 | 272 | -27 | 116 | 92 |
| 31 Dec 20 | 225 | -60 | 118 | 98 |
| 30 Sep 20 | 235 | -56 | 120 | 104 |
| 30 Jun 20 | 241 | -42 | 122 | 110 |
| 31 Mar 20 | 224 | -82 | 126 | 123 |
| 31 Dec 19 | 272 | -76 | 140 | 133 |
| 30 Sep 19 | 280 | -95 | 151 | 141 |
| 30 Jun 19 | 287 | -92 | 148 | 147 |
| 31 Mar 19 | 284 | -99 | 155 | 154 |
| 31 Dec 18 | 251 | -114 | 146 | 165 |
| 30 Sep 18 | 202 | -147 | 136 | 177 |
| 30 Jun 18 | 145 | -210 | 140 | 190 |
| 31 Mar 18 | 94 | -243 | 125 | 200 |
| 31 Dec 17 | 28 | -292 | 107 | 208 |
| 30 Sep 17 | 6 | -301 | 92 | 214 |
| 30 Jun 17 | 0 | -289 | 74 | 216 |
| 31 Mar 17 | 0 | -278 | 61 | 217 |
| 31 Dec 16 | 0 | -276 | 54 | 223 |
| 30 Sep 16 | 0 | -265 | 47 | 219 |
| 30 Jun 16 | 0 | -260 | 42 | 219 |
| 31 Mar 16 | 0 | -258 | 35 | 224 |
| 31 Dec 15 | 0 | -239 | 32 | 208 |
| 30 Sep 15 | 0 | -225 | 30 | 196 |
| 30 Jun 15 | 0 | -200 | 25 | 176 |
| 31 Mar 15 | 0 | -175 | 24 | 151 |
| 31 Dec 14 | 0 | -142 | 19 | 123 |
| 30 Sep 14 | 0 | -110 | 14 | 96 |
| 30 Jun 14 | 0 | -89 | 13 | 76 |
| 31 Mar 14 | 0 | -63 | 11 | 52 |
| 31 Dec 13 | 0 | -55 | 10 | 45 |
Quality Earnings: PBYI has high quality earnings.
Growing Profit Margin: PBYI became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBYI has become profitable over the past 5 years, growing earnings by 58.9% per year.
Accelerating Growth: PBYI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PBYI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: PBYI's Return on Equity (18%) is considered low.